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BackgroundThe intestines are key for the absorption of nutrients and water as well as drugmetabolism, and it is well known that there are clear differences in the expressionprofile of drug metabolism enzymes along the intestinal tract. Yet only a few studieshave thoroughly investigated regional differences in human intestinal drugmetabolism. In this study, we evaluated phase I and phase II metabolism in matchedhuman ileum and colon precision-cut intestinal slices (PCIS).
MethodsTo this end, human PCIS were incubated for 3 h with testosterone and 7-hydroxycoumarin (7-HC) to examine phase I and phase II metabolism, respectively.Metabolite formation was assessed by high-performance liquid chromatographyanalysis.
ResultsOur results demonstrated that androstenedione, 6β-hydroxytestosterone, 2β-hydroxytestosterone, and 7-HC sulfate, were predominantly formed in the ileum, while15α-hydroxytestosterone and 7-HC glucuronide were mainly produced in the colon.Moreover, we also observed sex differences in phase II metabolite formation, whichappeared to be higher in males as compared to females.
ConclusionsTaken together, we demonstrated that phase I metabolism predominantlyoccurs in ileum PCIS, while phase II metabolism mostly takes place in colon PCIS.Moreover, we revealed that human PCIS can be used to study both regional and sexdifferences in intestinal metabolism.
Keywords:Cytochrome P450, gastrointestinal tract, glucuronidation/UDP-glucuronyltransferases/UGT, HPLC,metabolite disposition, sulfate conjugation/sulfotransferases/SULT.
Abbreviations:15α-TOH, 15α-hydroxytestosterone; 2β-TOH, 2β-hydroxytestosterone; 6β-TOH, 6β-hydroxytestosterone; 7-HC, 7-hydroxycoumarin; CAR, constitutive androstane receptor; CYP,cytochrome P450; DMEs, drug metabolizing enzymes; hPCIS, human precision-cut intestinal slices;HPLC, high-performance liquid chromatography; KHB, Krebs-Henseleit Buffer; PCIS, precision-cutintestinal slices; PCTS, precision-cut tissue slices; PXR, pregnane X receptor; P450, cytochrome P450;SULTs, sulfotransferase; TT, testosterone; UGTs, uridine 5’-diphospho-N-acetylgalactosamineglycosyltransferase.
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INTRODUCTIONIn addition to the absorption of nutrients and water, the intestines also fulfill animportant role in drug metabolism.1–3 This is illustrated by the high expression level ofdrug metabolizing enzymes (DMEs) along the intestinal tract.4,5In the human body, xenobiotics are metabolized via various pathways includingphase I and phase II metabolism. Phase I reactions are oxidation, reduction, andhydrolysis processes. These chemical reactions change the biological activity of theparent compound rendering it less or completely inactive.6 In the intestines, the mostabundant group of enzymes belong to the cytochrome P450 subfamily 3A. Nonetheless,the expression profile of CYP enzymes differs along the intestinal tract and speciesdifferences are apparent.7 For instance, CYP3A13 is more common in the mouseintestine while CYP3A4/5 is predominantly found in the human small intestine.7 Inaddition, it has been demonstrated that the mRNA levels of CYP isoforms diminishalong the intestinal tract, with the highest CYP expression in the duodenum and thelowest in the colon.7,8 In order to study metabolic activity, it is key to use suitablesubstrates. In the last decades, testosterone (TT9; Figure 1) and 7-hydroxycoumarin(7-HC9; Figure 1) have been widely used to examine phase I and phase II metabolism,respectively.10,11 TT can be used to study phase I metabolism since this hormone ishydroxylated by cytochrome P450 enzymes (CYP3A, CYP2A, and CYP2B).12–15Phase II reactions are conjugation reactions, e.g. glucuronidation and sulfation,that improve the solubility of endo- and xenobiotics.6 7-HC can be used to examine bothreactions,15 glucuronidation of 7-HC is mediated by uridine 5’-diphospho-N-acetylgalactosamine glycosyltransferase (UGTs), while sulfotransferase (SULTs)catalyze sulfation reactions.3,16Until now, most in vitro studies on intestinal metabolism were conducted byusing subcellular fractions like microsomes or enterocytes. Using advanced analyticalmethods, it has been demonstrated that the majority of drug metabolism enzymes canbe detected in intestinal microsomes. Moreover, it has been shown that microsomescan be used to investigate enzymatic activity and the intestinal contribution to firstpass drug metabolism.17–19However, microsomes, lack membrane transporters as wellas low abundant enzyme systems and the enzymatic activity in microsomes is highlydependent on the isolation method.14,20–22
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Recently, it has been demonstrated that precision-cut tissue slices (PCTS) canbe used to study intestinal drug metabolism.23 In this ex vivo model, all the differentcells that constitute an organ are maintained in their original environment allowing forcell-cell and cell-matrix interactions.24 In precision-cut intestinal slices (PCIS) theorganization of the intestinal villi and microvilli is well conserved.25 Also, the methodis highly efficient, since a large number of slices can be prepared from a small tissuesample, and the slices are relatively easy to process.14 Here, we studied the regionaldifferences in intestinal metabolism by using matched human ileum and colon PCISfocusing on both phase I and phase II metabolism.
MATERIALS AND METHODS
ChemicalAll chemicals were obtained from Sigma (Zwijndrecht, the Netherlands) unlessstated otherwise. Stock solutions of testosterone (TT) and 7-hydroxycoumarin (7-HC)were prepared in methanol and stored at -20 °C.
Preparation of intestinal slicesHealthy human ileum and colon tissue was obtained following hemicolectomyfor adenocarcinoma (See Table 1 for patient characteristics). Use of human tissue wasapproved by the Medical Ethical Committee of the University Medical CentreGroningen (UMCG), according to Dutch legislation and the Code of Conduct for dealingresponsibly with human tissue in the context of health research (www.federa.org),refraining the need of written consent for ‘further use’ of coded-anonymous humantissue. The procedures were carried out in accordance with the experimental protocolsapproved by the Medical Ethical Committee of the UMCG.
Slicing of precision-cut intestinal slicesPreparation of intestinal slices (PCIS) was carried out according to the protocolof de Graaf et al., 2010.26 In short, intestinal tissue was cleansed by flushing Krebs-Henseleit Buffer (KHB) through the lumen and subsequently divided into 2-cmsegments. Afterwards, intestinal cores were prepared using 3% (w/v) agarose (Sigma-Aldrich, Steinheim, Germany) in 0.9% NaCl at 37 °C and embedded in an agarose core-
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embedding unit. Next, PCIS were prepared using a Krumdieck tissue slicer. PCIS had awet weight of approximately 3 mg, and an estimated thickness of 300-400 μm.Following slicing, PCIS were directly transferred to KHB to prevent loss of viability.
Table 1. Characteristics of human PCIS from the human donors.
Human ID Gender* AgePatient 1 M 64Patient 2 M 52Patient 3 M 88Patient 4 F 79Patient 5 F 65Patient 6 M 64Patient 7 F 81*M=male; F=female
Incubation of slicesAfter slicing, PCIS were cultured in 12-well plates containing Williams’ MediumE + Glutamax (Gibco, New York, NY) supplemented with 14 mM Glucose (Merck,Darmstadt, Germany), 50 µg/ml gentamycin (Gibco) and 2.5 µg/ml fungizone(amphotericin B; Invitrogen, Paisly, Scotland). Slices were cultured at 37 °C in an 80%O2/5% CO2 atmosphere, while horizontally shaken at 90 rpm (amplitude 2 cm). Formetabolism experiments, PCIS were incubated with TT (250 µM) or 7-HC (500 µM) for3 h.
ViabilityViability of PCIS was assessed by measuring the adenosine triphosphate (ATP)content of the slices using an ATP bioluminescence kit (Roche diagnostics, Mannheim,Germany), as previously described.26 Determined ATP values (picomoles) werenormalized to the total amount of protein (micrograms) estimated by the Lowrymethod (BIO-rad RC DC Protein Assay, Bio Rad, Veenendaal, The Netherlands). Resultsare shown as relative values compared to the related controls.
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Figure 1. Testosterone and 7-hydroxycoumarin metabolism pathways: (A) Phase I; (B) Phase II.
Metabolite analysis
Testosterone. After incubation with testosterone (TT), PCIS and medium werecollected and stored at -20 °C until further use. Sample extraction and high-
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performance liquid chromatography (HPLC) analysis was performed as describedearlier.27
7-Hydroxycoumarin. 7-Hydroxycoumarin (7-HC) and their metabolites do notaccumulate in PCIS; therefore the analysis was performed using medium samplesonly.10,28 After incubation, samples were collected and stored at -20 °C until use. Levelsof 7-HC glucuronide and 7-HC sulfate were determined via HPLC analysis as describedpreviously.14
StatisticsStatistics were performed using GraphPad Prism 6.0 via two-tailed Student's t-test and Pearson rank correlation as appropriate. A minimum of three differentintestines was used for each experiment, using 3–6 slices from each intestine percondition. The results are expressed as mean ± standard error of the mean (SEM).Statistical differences in ATP levels were determined using the values relative to thecontrol values. Differences between groups were considered to be statisticallysignificant when P < 0.05.
RESULTS
Viability of ileum and colon slicesOur laboratory previously demonstrated that rat PCIS can be used to studyintestinal metabolism in vitro. To gain more insight into human metabolism, weprepared matched ileum and colon PCIS, allowing us to study regional differences inintestinal metabolism. First, we characterized viability of the slices by determining theATP content. As shown in Figure 2, the ATP content of human ileum PCIS significantlyincreased after 3 h of culture, as compared to the 0-hour control, after which the levelsremained stable. Similar results were obtained with colon PCIS, indicating thatintestinal slices remain viable in culture for at least 24 h.
Assessment of phase I metabolism in ileum and colonTo study phase I metabolism, we incubated ileum and colon PCIS with TT. Asshown in Figure 3, several testosterone metabolites were formed in both ileum andcolon slices, e.g. androstenedione, 6β-hydroxytestosterone (6β-TOH), 15α-
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hydroxytestosterone (15α-TOH), and 2β-hydroxytestosterone (2β-TOH). However, there was a clear distinction between the metabolite levels in ileum and colon (Figure 
3, n=5). Androstenedione, formed by 17β-hydroxysteroid dehydrogenase, is the main TT metabolite that can be found in both the ileum and colon with a mean concentration of 9.55 ± 2.27 (range 3.0-15.6) and 4.34 ± 0.96 (range 2.0-9.3) pmol/µg protein, respectively. 6β-TOH was also found in all patient samples, however, the levels were approximately 4.2-fold higher in the ileum than in the colon (Figure 3, n=5). In addition, 2β-TOH levels also appeared to be higher in the ileum than in the colon, with a mean concentration of 0.24 ± 0.11 and 0.06 ± 0.01 pmol/µg protein, respectively, although differences were not statistically significant. Regarding 15α-TOH, no differences were observed. Overall, these results suggest that the ileum plays a bigger role in phase I metabolism as compared to the colon (Supplementary Table S1).
Figure 2. Viability (relative value) of human ileum and colon slices (n=7). Data are expressed asmean +/- SEM. *p<0.05 vs. control (0 h).
Assessment of phase II metabolism in ileum and colonNext, we investigated phase II metabolism by using 7-HC. As shown in Figure
4, both glucuronidation and sulfation reactions took place in the ileum and the colon(n=7). Although not statistically significant, the concentration of 7-HC glucuronide was2.2-fold higher in the colon as compared to the ileum. In contrast, there was nostatistically -significant difference in sulfation in the ileum and colon. Furthermore,
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Figure 4 shows that, in the colon, 7-HC glucuronide levels were 5.8 times higher ascompared to 7-HC sulfate (p<0.05). Taken together, these results suggest that phase IIreactions are more prevalent in the colon than the ileum, especially regardingglucuronidation.
Figure 3. Testosterone metabolite formation in human ileum and colon slices (n=5). Data areexpressed as mean +/- range. *p<0.05.Furthermore, we studied the overall occurrence of phase I and II metabolism inthe ileum and colon by comparing relative metabolite formation. A ratio higher thanone (r>1) indicates that the metabolites were more prevalent in the ileum than thecolon. Conversely, a ratio of less than 1 (r<1) shows that the metabolites were mainlypresent in the colon instead of the ileum. As shown in Figure 5, androstenedione, 6β-TOH, 2β-TOH, and 7-HC sulfate, were predominantly found in the ileum instead of thecolon. While, 15α-TOH (0.69), and 7-HC glucuronide (0.45) levels were higher in thecolon rather than the ileum (Supplementary Table 1).Moreover, as illustrated in Figure 6, we also observed sex differences in phaseII metabolite formation, which appeared to be higher in men as compared to women.
Influence of viability on metabolite formationTo exclude the possibility that metabolite formation was influenced by theviability of the slices we performed a correlation analysis, which revealed no significant
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correlation between the ATP content of the slices and the formation of most phase Iand phase II metabolites, both in the ileum and colon. However, we found a trendtowards a negative correlation between ATP levels and 7-HC glucuronide in the ileum(p=0.08, r=0.7).
Figure 4. 7-Hydroxycoumarin metabolite formation in human ileum and colon slices (n=7). Dataare expressed as mean +/- SEM. *p<0.05. Zero metabolite formation due to the limit of detection of theHPLC.
Figure 5. Testosterone and 7-Hydroxycoumarin metabolite formation in human ileum and colon
slices (n=5-7). Data are expressed as mean +/- range.
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Correlation between phase I and phase II metabolismFinally, to understand better the relationship between phase I and phase IImetabolism, we investigated the correlation between all the studied metabolites.As demonstrated in Figure 7, we found a strong positive correlation in theileum between 2β-TOH and 6β-TOH, 7-HC glucuronide and 6β-TOH, 7-HC sulfate and6β-TOH, 7-HC glucuronide and 2β-TOH, as well as 7-HC sulfate and 2β-TOH(Supplementary Table S2). There was also a strong positive correlation between 7-HC glucuronide and 15α-TOH, as well as 7-HC sulfate and 7-HC glucuronide in the colon(Supplementary Table S2). However, we did not observe a correlation between themetabolic activity of phase I and phase II enzymes in matched slices (Supplementary
Figures S1 and S2).
Figure 6. Sex differences on phase II metabolism of human ileum and colon slices: (A) 7-HCGlucuronide; (B) 7-HC Sulfate. Data are expressed as mean +/- range.
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DISCUSSIONThe intestines fulfill an important role in drug metabolism, and it is known thatthe expression levels of the involved enzymes differ along the intestinal tract. However,studies in humans are lacking, especially with regards to intraindividual differences inregional metabolism.  Here, we evaluated the differences in phase I and II metabolismusing matched ileum and colon hPCIS.Our results demonstrated that the ATP level, as a marker of viability, increasedafter 3 h of culture and remained elevated for 24 h in both human ileum and colon PCIS.A similar observation was previously made using rat PCIS.15 In addition, we found nocorrelation between ATP levels and the formation of phase I and phase II metabolites,in both ileum and colon (Supplementary Figures S3 and S4). This result emphasizesthat the viability of PCIS had no impact on the metabolic activity of phase I and phaseII enzymes.A unique aspect of this study was the fact that we were able to use matchedileum and colon hPCIS. This allowed us to show that there is no correlation betweenthe metabolic rate of phase I and phase II enzymes in matched slices (Supplementary
Figures S1 and S2). This strongly suggests that the regional drug metabolism capacityis differently regulated within one human being. Furthermore, pharmacokinetics andbioavailability of drugs are greatly affected in patients with a short small bowelfollowing gastro-intestinal surgery, and the changes will vastly differ betweenpatients.29,30 Studies with matched hPCIS can aid in the identification of suitabletherapies for this patient population.We demonstrated that testosterone metabolism mostly occurred in the ileum.This result is in line with a previous study showing that protein levels of CYP3A, whichexhibits testosterone 6β-hydroxylase activity,31 is highest in the proximal region of theintestine and declines in the distal part.21,32–34 In addition, other studies revealed thatCYP3A and CYP2C are the major intestinal CYPs, accounting for approximately 80%and 18%, respectively, of all CYPs.19,35 In line with our findings, Thelen and Dressmanalso showed that CYP3A content is generally higher in the proximal region of theintestine.35Our results further demonstrated that metabolism of 7-HC mostly took place inthe colon. These findings corroborate previous works showing that UGTs are primarily
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found in the colon.36,37 In contrast, Drozdzik et al. has reported that UGT1A1 was themost abundant UGT in jejunum, compared to other intestinal segments.21 However,they only measured mRNA level and protein content, not enzyme activity.Previously, the metabolic activity in intestinal slices and intestinal ratmicrosomes has been compared. The results showed that the metabolic rates inintestinal slices was significantly higher for all substrates studied (including TT, 3- to29-fold) compared with the microsomes.7 In addition, in agreement with our findings,Ho et al. described that CYP3A4 (TT as a substrate) was the most active enzymes incryopreserved enterocytes from human small intestines followed by UGT and SULT (7-HC as a substrate), respectively.38Furthermore, we also discovered a strong correlation between several productsformed by CYP3A (e.g. 2β-TOH and 6β-TOH),31,39 CYP2A (15α-TOH),13 UGT1A (7-HCglucuronide)16 and SULT1 (7-HC sulfate)16 in both the ileum and colon. These resultssuggest that there might be a shared regulatory mechanism between phase I and phaseII enzymes. Indeed, work by Xie and colleagues demonstrated that the constitutiveandrostane receptor (CAR) and pregnane X receptor (PXR) are involved in theregulation of CYP3A and CYP2B,40 as well as specific UGT1A isoforms.41 In addition,Maglich et al. has shown that CAR regulates CYP2A6 and SULT1.42 Thus, it is clear thatseveral signaling pathways can regulate both phase I and phase II enzymes.We also observed that the rate of phase II metabolism was higher in male PCISas compared to female PCIS. To the best of our knowledge, sex differences in humanintestinal metabolism have not been reported before. However, using human livermicrosomes, Court et al. previously established that acetaminophen metabolism,catalyzed by UGT1A1, UGT1A6, and UGT1A9, was higher in males as compared tofemales.43 Men also show a higher rate of clearance of several benzodiazepines (e.g.diazepam, chlordiazepoxide, and olanzapine), which is catalyzed by CYP1A2.Furthermore, men more rapidly clear chloroxazone, a CYP2E1 substrate.44 Also, it isclear that endogenous sex hormones can impact hepatic enzyme activity resulting insex differences in pharmacokinetics.44 However, Miyauchi et al. reported that therewas no significant difference between men and women in the expression level of CYPsand UGTs in human jejunal tissues.45 In addition, Her et al. described a large variationin the jejunal expression of SULT1E1 and SULT2A1 independent of gender or age.46
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Thus, more research is needed to characterize fully sex-based differences in intestinaldrug metabolism.
CONCLUSIONPCIS is a promising model to investigate intestinal drug metabolism. Based onthis study, it can be concluded that there is a significant difference in the rate of phaseI and II metabolism in the ileum and the colon. We demonstrated that phase Imetabolism predominantly occurs in ileum PCIS, while phase II metabolism mostlytakes place in colon PCIS. Moreover, our study revealed that PCIS could be used toinvestigate sex differences in drug metabolism.
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TABLE S1.Metabolic rates during 3 h of incubation in small intestinal (ileum) and colon slices (Data areexpressed as mean +/- SEM, n=5-7).
*Significantly different from ileum with p < 0.05ϮSignificantly different from 7-HC Sulfate colon with p < 0.05
TABLE S2. Correlations between phase I and phase II metabolite formation in the ileum (all data abovethe black box) and the colon (all data below the black box); n=5-7.Correlationvs. Andro 6β-TOH 15α-TOH 2β-TOH 7-HCGlucuronide 7-HCSulfate
Andro p=0.13r=0.76 p=0.99r=-0.01 p=0.27r=0.62 p=0.34r=0.54 p=0.32r=0.56
6β-TOH p=0.09r=0.81 p=0.45r=0.44 p=0.01r=0.97 p=0.01r=0.94 p=0.02r=0.93
15α-TOH p=0.74r=0.21 p=0.54r=0.37 p=0.50r=0.40 p=0.26r=0.63 p=0.39r=0.50
2β-TOH p=0.34r=-0.55 p=0.97r=0.63 p=0.93r=0.06 p=0.01r=0.94 p=0.001r=0.99
7-HC
Glucuronide
p=0.40r=0.49 p=0.13r=0.80 p=0.02r=0.94 p=0.91r=0.07 p=0.11r=0.65
7-HC
Sulfate
p=0.40r=0.49 p=0.59r=0.33 p=0.10r=0.81 p=0.48r=-0.42 p=0.04r=0.77: Significantly different and strongly correlated (p<0.05, r>+/-0.5)
Metabolite Formed 0-3 hours (pmol/µg protein) Ratio (Ileum/Colon)Ileum ColonAndrostenedione 9.55 ± 2.27 4.34 ± 0.96 2.206β-TOH 1.78 ± 0.65 0.42 ± 0.05* 4.2415α-TOH 0.33 ± 0.08 0.48 ± 0.08 0.692β-TOH 0.24 ± 0.11 0.06 ± 0.01 4.007-HC Glucuronide 27.16 ± 7.27 59.37 ± 20.85Ϯ 0.457-HC Sulfate 17.59 ± 6.34 10.29 ± 3.97 1.71
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Figure S1. The metabolism rate of phase I in human ileum and colon PCIS: (A) Patient 1; (B) Patient2; (C) Patient 3; (D) Patient 4; (E) Patient 5 (Each data was obtained triplicates; Zero metaboliteformation due to the limit of detection of the HPLC).
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Figure S2. The metabolism rate of phase II in human ileum and colon PCIS: (A) Patient 1; (B) Patient2; (C) Patient 3; (D) Patient 4; (E) Patient 5; (F) Patient 6; Patient 7 (Each data was obtained triplicates;Zero metabolite formation due to the limit of detection of the HPLC).
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Figure S3. Correlations of ATP with the phase I metabolite formation: in the ileum (A-D) and colon(E-H), n=5.
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Figure S4. Correlations of ATP with the phase II metabolite formation: in the ileum (A and B) andcolon (C and D), n=7.
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